In a comparison of COVID-19 vaccines, the mRNA vaccine sustained higher anti-S IgG, while the Ad-vector had superior ...

Moderna Inc.’s shares fell after US regulators refused to review its novel mRNA flu vaccine, creating regulatory chaos for the pharmaceutical industry and offering another example of the Trump ...

The company is “seeking clarity from the FDA on what has changed” from the previous written guidance it received, Moderna President Stephen Hoge said in an interview. “It’s a total surprise” the ...

America’s drug safety agency declined to review a next-gen flu vaccine that uses the same tech as the coronavirus shots ...

This week, vaccine manufacturer Moderna revealed that Vinaya Prasad, the top vaccine regulator at the Food and Drug Administration (FDA)—which is a part of HHS— declined to even consider the safety ...

The Food and Drug Administration is refusing to consider Moderna's application for a new flu vaccine made with mRNA ...

Senior FDA official Vinay Prasad reportedly overrode his staff in deciding to reject Moderna's application for a new seasonal flu shot.

Moderna's flu vaccine faces FDA hurdles as the agency rejects its approval due to trial comparison concerns. Learn more here.